StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Research analysts at StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Marinus Pharmaceuticals Stock Performance

Shares of Marinus Pharmaceuticals stock opened at $0.55 on Thursday. The stock has a market capitalization of $30.32 million, a PE ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $8.90. The stock has a 50 day moving average price of $0.55 and a two-hundred day moving average price of $0.69.

Institutional Trading of Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new position in shares of Marinus Pharmaceuticals in the fourth quarter valued at $36,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in shares of Marinus Pharmaceuticals in the 4th quarter worth about $54,000. World Investment Advisors LLC bought a new position in Marinus Pharmaceuticals in the 3rd quarter valued at about $104,000. Deltec Asset Management LLC bought a new position in Marinus Pharmaceuticals in the 4th quarter valued at about $107,000. Finally, XTX Topco Ltd boosted its stake in Marinus Pharmaceuticals by 1,564.7% during the 4th quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock valued at $118,000 after purchasing an additional 206,614 shares during the last quarter. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.